🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,263 results for “Cancer” Clear

  1. LETROZOLE, PALBOCICLIB, Inavolisib placebo, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, Letrozol STADA® 2,5 mg Filmtabletten, INAVOLISIB, IBRANCE 100 mg film-coated tablets, INAVOLISIB, RIBOCICLIB, PALBOCICLIB, RIBOCICLIB, PALBOCICLIB

    Roche Registration Limited

    Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Hormone Receptor-Positive, human epidermal growth factor receptor 2- (HER2-) negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  2. LEUPRORELIN ACETATE, BAY 1841788, NUBEQA 300 mg film-coated tablets, TRIPTORELIN, DEGARELIX, GOSERELIN

    Cancer Prevention Pharma (Ireland) Limited

    Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).

    phase 3 small molecule active

    1 trial

  3. LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, ANASTROZOLE, GOSERELIN, LETROZOLE, GOSERELIN, EXEMESTANE, RIBOCICLIB

    Novartis Ophthalmics Europe

    HR-positive HER-2- negative Breast Cancer

    phase 3 small molecule active

    1 trial

  4. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  5. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  6. LIBTAYO 350 mg concentrate for solution for infusion.

    Partner Therapeutics Limited

    Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%

    phase 3 small molecule active

    1 trial

  7. LIBTAYO 350 mg concentrate for solution for infusion., Armisarte 25 mg/ml concentrate for solution for infusion, Gemcitabine 2 g Powder for Solution for Infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion

    Pharma Mar S.A.

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  8. LIBTAYO 350 mg concentrate for solution for infusion., Vinorelbine 10 mg/ml concentrate for solution for infusion, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, THIO, Gemcitabine 1 g Powder for Solution for Infusion

    MAIA Biotechnology

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  9. LOMUSTINE

    Cancer Prevention Pharma (Ireland) Limited

    Glioblastoma

    phase 3 small molecule active

    1 trial

  10. LORLATINIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Advanced ALK positive non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  11. LORLATINIB, AXITINIB, AVELUMAB, AXITINIB, TALAZOPARIB, TALAZOPARIB

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Cancer

    phase 3 small molecule active

    1 trial

  12. Lenvatinib, Belzutifan, Lenvatinib

    Merck Sharp and Dohme

    Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorectal cancer, pancreatic ductal adenocarcinoma, biliary tract cancer, non-MSIH/dMMR endometrial cancer, esophageal squamous cell carcinoma, Advanced Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, von Hippel-Lindau (VHL)Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor, Advanced Solid Tumors With HIF-2α related Genetic Alterations

    phase 3 small molecule active

    1 trial

  13. Lerotinib

    Sunshine Biopharma

    Esophageal Cancer

    phase 3 small molecule active

    1 trial

  14. Leuprorelin

    Takeda Pharmaceuticals International AG

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  15. Locametz 25 micrograms kit for radiopharmaceutical preparation, ABIRATERONE , LEUPRORELIN , HISTRELIN , ENZALUTAMIDE , TRIPTORELIN , NILUTAMIDE , Pluvicto 1 000 MBq/mL solution for injection/infusion, GOSERELIN , DEGARELIX , BICALUTAMIDE , BUSERELIN , -, RELUGOLIX , APALUTAMIDE , DAROLUTAMIDE , FLUTAMIDE

    Novartis Ophthalmics Europe

    PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)

    phase 3 small molecule active

    1 trial

  16. Locametz 25 micrograms kit for radiopharmaceutical preparation, PIFLUFOLASTAT (18F), PIFLUFOLASTAT (18F), Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Ophthalmics Europe

    Oligometastatic prostate cancer (OMPC)

    phase 3 small molecule active

    1 trial

  17. Lonsurf 15 mg/6.14 mg film-coated tablets, Relatlimab + Nivolumab Fixed Dose Combination (FDC), Lonsurf 20 mg/8.19 mg film-coated tablets, Stivarga 40 mg film-coated tablets

    Bristol-Myers Squibb / Pfizer EEIG

    Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  18. Luveltamab tazevibulin

    SUTRO BIOPHARMA, INC.

    Ovarian Cancer

    phase 3 small molecule terminated

    1 trial

  19. Lynparza 100 mg film-coated tablets, ABIRATERONE , PREDNISOLONE , Lynparza 150 mg film-coated tablets

    AstraZeneca AB

    Metastatic castration-resistant prostate cancer

    phase 3 small molecule active

    1 trial

  20. Lynparza 100 mg film-coated tablets, Placebo - film-coated tablets, Lynparza 150 mg film-coated tablets

    AstraZeneca AB

    Breast Cancer

    phase 3 small molecule active

    1 trial

  21. Lynparza 100 mg film-coated tablets, Sodium Chloride Intravenous Infusion BP 0.9% w/v Solution for Infusion (not authorised), Placebo film-coated tablet (Not Authorised), Lynparza 150 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., MYCOPHENOLATE MOFETIL, INFLIXIMAB, BEVACIZUMAB

    AstraZeneca AB

    Newly diagnosed advanced (FIGO stage III-IV) high grade epithelial ovarian, fallopian or primary peritoneal cancer

    phase 3 small molecule active

    1 trial

  22. Lynparza 150 mg film-coated tablets, Lynparza 100 mg film-coated tablets

    AstraZeneca AB

    BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, prostate cancer, endometrium cancer

    phase 3 small molecule active

    1 trial

  23. Lynparza 150 mg film-coated tablets, PACLITAXEL , CARBOPLATIN , GEMCITABINE , DOXORUBICIN , Lynparza 100 mg film-coated tablets, CISPLATIN , BEVACIZUMAB

    Fondazione Telethon ETS

    Recurrent ovarian cancer

    phase 3 small molecule active

    1 trial

  24. MEDI4736 Placebo, DURVALUMAB

    CERO THERAPEUTICS HOLDINGS, INC.

    Completely resected primary stage IB (≥ 4cm), II and IIIA non-small cell lung cancer patients

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources